View printer-friendly version

Download PDF

Emergent BioSolutions to Webcast Presentation at Credit Suisse First Annual Antibody Day

ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 29, 2013– Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Credit Suisse First Annual Antibody Day in New York on May 10, 2013 at 9:30 AM Eastern. During the presentation, a member of the company’s management team will provide an overview of the company’s lead clinical development candidate, the TRU-016 ADAPTIR™ (Modular Protein Technology) therapeutic, as well as a discussion of the company’s ADAPTIR platform and certain pre-clinical programs based on the ADAPTIR platform. The webcast of this presentation will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under “Investors.”

About the ADAPTIR Platform

ADAPTIR bispecific proteins are modular, single chain polypeptides that comprise two separate binding domains (VL and VH), a hinge segment, and an effector domain (huFc). They have a differentiated structure from monoclonal antibodies and can generate a unique signaling response. In addition, ADAPTIR proteins may mediate complement dependent cytotoxicity and Fc dependent cytotoxicity, similar to monoclonal antibodies.

ADAPTIR^TM and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All rights reserved.

About Emergent BioSolutions Inc.

Emergent BioSolutions is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Additional information about us may be found at www.emergentbiosolutions.com.

Follow us on Twitter: @emergentbiosolu.

Source: Emergent BioSolutions Inc.